Orlowski RZ - Search Results

1

Initial therapy of multiple myeloma patients who are not candidates for stem cell transplantation.

Orlowski RZ. Orlowski RZ. Hematology Am Soc Hematol Educ Program. 2006:338-47. doi: 10.1182/asheducation-2006.1.338. Hematology Am Soc Hematol Educ Program. 2006. PMID: 17124081 Review.

2

Clinical course of thrombocytopenia in patients treated with imatinib mesylate for accelerated phase chronic myelogenous leukemia.

van Deventer HW, Hall MD, Orlowski RZ, Mitchell BS, Berkowitz LR, Hogan C, Dunphy CH, Koehler J, Shea TC. van Deventer HW, et al. Among authors: orlowski rz. Am J Hematol. 2002 Nov;71(3):184-90. doi: 10.1002/ajh.10215. Am J Hematol. 2002. PMID: 12410573 Free article. Clinical Trial.

3

Phase I trial of the proteasome inhibitor PS-341 in patients with refractory hematologic malignancies.

Orlowski RZ, Stinchcombe TE, Mitchell BS, Shea TC, Baldwin AS, Stahl S, Adams J, Esseltine DL, Elliott PJ, Pien CS, Guerciolini R, Anderson JK, Depcik-Smith ND, Bhagat R, Lehman MJ, Novick SC, O'Connor OA, Soignet SL. Orlowski RZ, et al. J Clin Oncol. 2002 Nov 15;20(22):4420-7. doi: 10.1200/JCO.2002.01.133. J Clin Oncol. 2002. PMID: 12431963 Clinical Trial.

4

Bortezomib and its role in the management of patients with multiple myeloma.

Orlowski RZ. Orlowski RZ. Expert Rev Anticancer Ther. 2004 Apr;4(2):171-9. doi: 10.1586/14737140.4.2.171. Expert Rev Anticancer Ther. 2004. PMID: 15056047 Review.

5

Phase 1 trial of the proteasome inhibitor bortezomib and pegylated liposomal doxorubicin in patients with advanced hematologic malignancies.

Orlowski RZ, Voorhees PM, Garcia RA, Hall MD, Kudrik FJ, Allred T, Johri AR, Jones PE, Ivanova A, Van Deventer HW, Gabriel DA, Shea TC, Mitchell BS, Adams J, Esseltine DL, Trehu EG, Green M, Lehman MJ, Natoli S, Collins JM, Lindley CM, Dees EC. Orlowski RZ, et al. Blood. 2005 Apr 15;105(8):3058-65. doi: 10.1182/blood-2004-07-2911. Epub 2004 Dec 30. Blood. 2005. PMID: 15626743 Free article. Clinical Trial.

6

Bortezomib in recurrent and/or refractory multiple myeloma. Initial clinical experience in patients with impared renal function.

Jagannath S, Barlogie B, Berenson JR, Singhal S, Alexanian R, Srkalovic G, Orlowski RZ, Richardson PG, Anderson J, Nix D, Esseltine DL, Anderson KC; SUMMIT/CREST Investigators. Jagannath S, et al. Among authors: orlowski rz. Cancer. 2005 Mar 15;103(6):1195-200. doi: 10.1002/cncr.20888. Cancer. 2005. PMID: 15690325 Free article.

7

Proteasome inhibitors in cancer therapy.

Orlowski RZ. Orlowski RZ. Methods Mol Biol. 2005;301:339-50. doi: 10.1385/1-59259-895-1:339. Methods Mol Biol. 2005. PMID: 15917644 Review.

8

The ubiquitin proteasome pathway from bench to bedside.

Orlowski RZ. Orlowski RZ. Hematology Am Soc Hematol Educ Program. 2005:220-5. doi: 10.1182/asheducation-2005.1.220. Hematology Am Soc Hematol Educ Program. 2005. PMID: 16304384

9

Emerging role of novel combinations for induction therapy in multiple myeloma.

Voorhees PM, Orlowski RZ. Voorhees PM, et al. Among authors: orlowski rz. Clin Lymphoma Myeloma. 2006 Jul;7(1):33-41. doi: 10.3816/CLM.2006.n.037. Clin Lymphoma Myeloma. 2006. PMID: 16879768 Review.

10

Extended follow-up of outcome measures in multiple myeloma patients treated on a phase I study with bortezomib and pegylated liposomal doxorubicin.

Biehn SE, Moore DT, Voorhees PM, Garcia RA, Lehman MJ, Dees EC, Orlowski RZ. Biehn SE, et al. Among authors: orlowski rz. Ann Hematol. 2007 Mar;86(3):211-6. doi: 10.1007/s00277-006-0220-3. Epub 2006 Dec 5. Ann Hematol. 2007. PMID: 17146676 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

368 results

Search Page

Filters